Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lyase PB72K is a recombinant enzyme developed by Proteos Biotech, a Spanish biotechnology company. It is a core component of the PBSerum product line, which utilizes recombinant enzymes for aesthetic and therapeutic applications. Lyase PB72K functions by enzymatically degrading polysaccharides within the extracellular matrix (ECM), specifically targeting components that contribute to edema and tissue congestion. This degradation increases tissue permeability and enhances the diffusion of other active substances. It is primarily indicated for the treatment of post-surgical fibrosis, scars, cellulite, and localized fat, and is also used in facial rejuvenation to improve skin health and texture. The enzyme is produced using proprietary bacterial-origin recombinant DNA technology and is supplied as a lyophilized powder to ensure maximum enzymatic activity upon reconstitution for injection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lyase PB72K.